25
Case Presentation: Polymer-Free DES Fausto Feres Alexandre Abizaid J. Ribamar Costa Junior Instituto Dante Pazzanese de Cardiologia Sao Paulo- Brazil SOLACI| Santiago de Chile August, 2011

Polymer-Free DES

Embed Size (px)

DESCRIPTION

SOLACI Chile Congress 2011. Dr. Fausto Feres. Find more presentations on the web site: www.solaci.org/

Citation preview

Page 1: Polymer-Free DES

Case Presentation:

Polymer-Free DESFausto Feres

Alexandre Abizaid

J. Ribamar Costa Junior

Instituto Dante Pazzanese de Cardiologia

Sao Paulo- Brazil

SOLACI|

Santiago de Chile

August, 2011

Page 2: Polymer-Free DES

VestaSync(MIV technologies)

Page 3: Polymer-Free DES

HAp Drug Delivery System

Stent Surface

HAp surface

modification

0.6um

HAp surface modification

loaded with encapsulated

drug formulation

0.6um

Stent Surface

Page 4: Polymer-Free DES

VESTASYNC Sirolimus DES

MicroPorous

Hydroxyapatite55ug Sirolimus

Formulation

0.7um

GenX Coronary Stent

Page 5: Polymer-Free DES

VESTASYNC Sirolimus DES

• Stent platform: GenX

• Surface modification: MicroPorous HAp

• Drug: Sirolimus

• Dose: 55 micrograms*

• Formulation: Lipids

• Encapsulation: Yes

• Polymer free: Yes

• Coating thickness: 0.6 microns

* VESTASYNC: 55ug/19mm stent or 2.9ug/mm

*Cypher: 140ug/18mm stent or 7.4 ug/mm

Page 6: Polymer-Free DES

Randomization (2:1)

Single de novo lesions in native vessels

RVD: 2.5 - 3.5 mm

Lesion length: ≤ 16mm

Stent diameter: 2.5. 3.0 e 3.5mm

Stent length: 19mm

Pre dilatation recommended

1 m 9 m 12 m

Clinical FU

Invasive FU (QCA & IVUS)

Primary endpoint In stent LLL & e % de NIH obstruction at 9 months

Secondary endpoints - MACE up to 5 years

- Acute success

-TLR, TVR & TLF up to 5 years

- Binary restenosis at 9 months

* DAPT for 6 months

Participating centers

• IDPC & Sta. Marcelina (Brazil)

24m

Study Design

QCA & IVUS corelabs

Cardiovascular Research Center (CRC) PI: Alexandre Abizaid

36m 48m 60m6 m

Page 7: Polymer-Free DES

Variables N= 15 pts

Quantitative Coronary Angiography

Minimum lumen diameter. mm 2.29 ± 0.38

Diameter of stenosis. (%) 15.9 ± 8.20

In stent Lumen loss. mm 0.36 ± 0.23

Binary restenosis. n(%) 0

Intravascular Ultrasound

Volume of NIH. mm3 6.1 ± 4.9

% stent obstruction 3.8 ± 2.3

Nine-month QCA & IVUS data

VestaSync I trial

Costa Jr J. et al. J. Am. Coll. Cardiol. Intv.. 2009

Page 8: Polymer-Free DES

4 MONTH- FU 9 MONTH- FU

PRE POST

4 MONTH-FU 9 MONTH-FU

Hig

her

LL

L

(0.8

0 m

m)

Page 9: Polymer-Free DES

PRE POST

4 MONTH- FU 9 MONTH- FU

Lo

wer

LL

L

(-0

.1 m

m)

CRC

Page 10: Polymer-Free DES

Case Presentation:

A journey to a simple LAD lesion

Page 11: Polymer-Free DES

Pre Procedure

Page 12: Polymer-Free DES

Pre Procedure

Page 13: Polymer-Free DES

Pre Dilatation

Page 14: Polymer-Free DES

1st Stent Implantation

Page 15: Polymer-Free DES

2nd Stent Implantation

Page 16: Polymer-Free DES

Angio post 2nd Stent

Page 17: Polymer-Free DES

Angio post 2nd Stent

Page 18: Polymer-Free DES

3rd Stent Implantation

Page 19: Polymer-Free DES

4th Stent Implantation

Page 20: Polymer-Free DES

Post Procedure

Page 21: Polymer-Free DES

Post Procedure

Page 22: Polymer-Free DES

Angio Follow-up at 9 months

Page 23: Polymer-Free DES

Angio Follow-up at 9 months

Page 24: Polymer-Free DES

IVUS Follow-up at 9 months

Page 25: Polymer-Free DES

FOLLOW-UP 9 MONTHS